Sitka Biopharma is developing a portfolio of novel therapeutics that utilize our proprietary HPG nanoparticle platform technology to improve the efficacy and tolerability of established drugs.

Our most advanced candidate, STK-01, is in late-stage preclinical development, with preparations for GLP IND-enabling studies underway. Other projects are currently in discovery research.